Encompass Health Co. (NYSE:EHC) Stock Position Reduced by Sanctuary Advisors LLC

Sanctuary Advisors LLC decreased its stake in Encompass Health Co. (NYSE:EHC) by 6.9% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 15,625 shares of the company’s stock after selling 1,160 shares during the quarter. Sanctuary Advisors LLC’s holdings in Encompass Health were worth $1,580,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of EHC. State Street Corp raised its holdings in shares of Encompass Health by 0.7% during the third quarter. State Street Corp now owns 3,025,769 shares of the company’s stock worth $292,410,000 after acquiring an additional 21,329 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Encompass Health by 1.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,819,345 shares of the company’s stock worth $156,083,000 after purchasing an additional 22,311 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Encompass Health by 1.2% during the 3rd quarter. Geode Capital Management LLC now owns 1,673,610 shares of the company’s stock valued at $161,781,000 after buying an additional 20,547 shares during the last quarter. Copeland Capital Management LLC grew its stake in shares of Encompass Health by 1.0% in the 3rd quarter. Copeland Capital Management LLC now owns 1,284,550 shares of the company’s stock valued at $124,139,000 after buying an additional 12,433 shares in the last quarter. Finally, Point72 Asset Management L.P. increased its holdings in Encompass Health by 2,458.5% in the third quarter. Point72 Asset Management L.P. now owns 869,104 shares of the company’s stock worth $83,990,000 after buying an additional 835,135 shares during the last quarter. Institutional investors and hedge funds own 97.25% of the company’s stock.

Encompass Health Stock Down 0.5 %

Shares of EHC opened at $93.83 on Friday. The company has a debt-to-equity ratio of 0.88, a quick ratio of 1.04 and a current ratio of 1.04. The company has a 50-day simple moving average of $99.50 and a 200-day simple moving average of $92.79. Encompass Health Co. has a 52 week low of $65.80 and a 52 week high of $104.55. The firm has a market capitalization of $9.45 billion, a P/E ratio of 22.66, a P/E/G ratio of 1.34 and a beta of 0.86.

Encompass Health (NYSE:EHC) last announced its quarterly earnings data on Monday, October 28th. The company reported $1.03 EPS for the quarter, topping analysts’ consensus estimates of $0.94 by $0.09. The company had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.33 billion. Encompass Health had a return on equity of 17.60% and a net margin of 8.10%. The company’s quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter last year, the company earned $0.86 EPS. On average, equities research analysts expect that Encompass Health Co. will post 4.29 earnings per share for the current year.

Encompass Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Thursday, January 2nd will be issued a $0.17 dividend. This represents a $0.68 annualized dividend and a yield of 0.72%. The ex-dividend date of this dividend is Thursday, January 2nd. Encompass Health’s dividend payout ratio (DPR) is presently 16.43%.

Analyst Ratings Changes

EHC has been the subject of a number of analyst reports. KeyCorp lifted their target price on shares of Encompass Health from $115.00 to $117.00 and gave the company an “overweight” rating in a research note on Tuesday, October 29th. Truist Financial reiterated a “buy” rating and issued a $116.00 price objective (up from $108.00) on shares of Encompass Health in a report on Wednesday, October 30th. Royal Bank of Canada raised their target price on Encompass Health from $105.00 to $110.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. UBS Group upped their price target on Encompass Health from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. Finally, Barclays raised their price objective on Encompass Health from $109.00 to $116.00 and gave the company an “overweight” rating in a research note on Tuesday, October 29th. Nine analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Encompass Health currently has a consensus rating of “Buy” and an average price target of $107.11.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.